Pharmaceutical

Cullinan advances multiple myeloma drug CLN-619 to a Phase I study

In addition to r/r multiple myeloma, the biotech is evaluating the drug as a treatment for advanced solid tumours alongside Keytruda.

Mar 1, 2024 - 18:00
Cullinan advances multiple myeloma drug CLN-619 to a Phase I study
In addition to r/r multiple myeloma, the biotech is evaluating the drug as a treatment for advanced solid tumours alongside Keytruda.
Read the original article

Tags:

Previous Article

Biden ‘continues to be fit for duty,’ his doctor says, after president undergoes...

Next Article

Panama updates their medicine regulatory system

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A deep dive on generative AI in health care, Pear sold for parts, and progress on stretchable skin

A deep dive on generative AI in health care, Pear sold ...

May 23, 2023

STAT+: Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards

STAT+: Federal regulators, scrambling to keep up with A...

Mar 4, 2024

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

China NMPA approves Zai Lab-argenx’s efgartigimod alfa ...

Jul 18, 2024